Universita' Di Pisa
- Address
- lock Available on a paid plan
Oncology and Hematologic Malignancies
At Universita' Di Pisa, a large share of the research portfolio focuses on cancer and blood disorders, with studies spanning breast cancer, colorectal cancer, lung cancer, gastric and esophageal cancers, urothelial carcinoma, and lymphomas. The trials are designed to test new treatment strategies, improve survival outcomes, and better define effective care for both early and advanced disease.
- Breast, colorectal, lung, and gastrointestinal cancers are heavily represented, reflecting broad interest in solid tumors.
- Lymphoma and leukemia studies explore better treatment options for hematologic malignancies.
- Several trials aim to improve adjuvant therapy, first-line treatment, and recurrence prevention.
Overall, the site supports a wide range of studies evaluating both established and newer approaches to help refine cancer care.
Cardiovascular and Thrombotic Disease Research
Clinical research in cardiovascular medicine at this site includes atrial fibrillation, coronary artery disease, heart failure, stroke, and broader atherosclerotic disease. These trials often focus on preventing major cardiovascular events, improving long-term protection, and identifying safer or more effective treatment options.
- Atrial fibrillation studies examine ways to reduce stroke and systemic embolism risk.
- Stroke and transient ischemic attack research looks at prevention and early recovery.
- Heart failure and atherosclerotic cardiovascular disease trials aim to improve outcomes in high-risk patients.
This area highlights a strong interest in preventing serious vascular complications and improving everyday cardiovascular care.
Neurology and Neurodegenerative Disorders
The neurology research program covers epilepsy, Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and other neurocognitive disorders. The main goals are to improve symptom control, slow disease progression, and support better quality of life for people living with chronic neurological conditions.
- Seizure disorders are studied to reduce seizure frequency and improve control.
- Parkinson’s disease and dementia trials focus on early-stage intervention and cognitive support.
- ALS and related neuromuscular conditions are included in research on disease management and progression.
These studies show a sustained commitment to both common and rare disorders affecting the brain and nervous system.
Autoimmune, Inflammatory, and Rheumatologic Diseases
Another major research theme is autoimmune disease, including systemic lupus erythematosus, Sjögren’s syndrome, IgG4-related disease, vasculitis, myositis, and systemic sclerosis. These trials are generally aimed at easing inflammation, improving symptom control, and finding more targeted treatments for complex immune-mediated conditions.
- Systemic lupus erythematosus and Sjögren’s syndrome are key areas of immune-focused research.
- Myositis, vasculitis, and IgG4-related disease studies address rare but serious inflammatory disorders.
- Several projects look at reducing disease activity while improving patient-reported symptoms and daily functioning.
This work reflects strong expertise in chronic immune and inflammatory diseases that often require long-term care.
Gastroenterology, Hepatology, and Metabolic Disease
Research in digestive and liver diseases includes ulcerative colitis, Crohn’s disease, primary biliary cholangitis, hepatocellular carcinoma, non-alcoholic steatohepatitis, and pancreatic and biliary tract cancers. The trials are designed to improve disease control, relieve symptoms, and evaluate new therapies for both inflammatory and malignant conditions.
- Inflammatory bowel disease studies focus on remission and symptom improvement.
- Liver disease and hepatobiliary cancer trials explore better treatment and recurrence prevention.
- Metabolic liver disorders such as NASH are included in efforts to address progressive chronic disease.
Across this field, the site combines research on chronic inflammation, liver injury, and gastrointestinal cancers.
Respiratory, Infectious, and Critical Care Studies
Clinical trials also address respiratory diseases, infections, and critical care conditions, including asthma, chronic obstructive pulmonary disease, pneumonia, sepsis, and viral infections such as COVID-19 and hepatitis B. The purpose of this research is to improve treatment effectiveness, reduce complications, and support recovery in high-risk patients.
- Asthma and COPD studies aim to improve breathing control and reduce flare-ups.
- Infection research includes bacterial, fungal, and viral illnesses that can lead to serious complications.
- Critical care trials examine outcomes in severe conditions such as ARDS and septic shock.
This area shows the breadth of the site’s work in both routine respiratory care and severe hospital-based illness.
Dermatology, Endocrinology, and Other Specialized Conditions
The site also conducts research in skin disease, endocrine disorders, and several rare conditions, including atopic dermatitis, hidradenitis suppurativa, psoriasis, thyroid eye disease, diabetes, and lipodystrophy. These trials are typically intended to test new therapies, improve symptom relief, and expand options for patients with difficult-to-treat conditions.
- Dermatologic diseases are studied for inflammation control and better skin symptom management.
- Thyroid eye disease and glaucoma research focus on preserving function and preventing progression.
- Metabolic and endocrine disorders include studies on diabetes, obesity, and rare hormone-related diseases.
These programs add important depth to the broader clinical trial landscape at the Dipartimento di Specilità Mediche.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 23 therapeutic areas and 15 of 351 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 323 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 70 by active trials.
lock +69 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB9trials
lock +37 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Universita' Di Pisa
lock Showing 1 of 225 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 24-Month, Multi-Centre, Open Label Phase IV Post Authorisation Efficacy Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in Patients with Partial Lipodystrophy | Chiesi Farmaceutici S.p.A. | Phase III | Recruiting | Dec 2023 | — |
IMP list
lock Showing 1 of 351 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cisplatin | 16 | Unknown | 2018-04-04 | 2025-12-19 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
